NewsBenzinga파시테아 테라퓨틱스, PAS-004 억제제의 1상 용량 증량 시험 결과 발표···용량 제한 독성 미발생, 참가자 중단 사례 없음, 3등급 이상 이상반응 미관찰 파시테아 테라퓨틱스, PAS-004 억제제의 1상 용량 증량 시험 결과 발표···용량 제한 독성 미발생, 참가자 중단 사례 없음, 3등급 이상 이상반응 미관찰 Benzinga 2026.10.23 13:20 (GMT+0) Open on Benzinga Other news New Address Withdraws 1.344 Billion PUMP From Coinbase, Worth About $3.87 Million Key Overnight and Morning News (November 16–17) Crypto Sectors Trade Mixed as DeFi Rises 1.67% While RWA and GameFi Each Drop Over 2% AI Lab Noeri, Founded by Stanford Professors, Raises $110M With Nvidia Among Investors Baidu Q3 Earnings: Total Revenue 30.8 Billion Yuan, AI Business Revenue Share Above Half for Third Straight Quarter Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC
Baidu Q3 Earnings: Total Revenue 30.8 Billion Yuan, AI Business Revenue Share Above Half for Third Straight Quarter
Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC